Pralsetinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark) and TLV (Sweden) recommended or restricted pralsetinib, while CIPM (Spain), HAS (France) and HIRA (South Korea), among others, did not recommend it.
The record spans 2.7 years, opening at AWMSG (Wales) on 8 Oct 2021 and running to 16 Jun 2024.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for pralsetinib, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 4 of 13 records date from 2023 or later.
Against its own class, pralsetinib is an outlier: 25% of its decisive outcomes were positive, where molecules sharing ATC class L01E average 75%.
3 distinct indication wordings are recorded for pralsetinib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess pralsetinib, on 8 Oct 2021; HIRA (South Korea) did not open a file until 6 Jul 2023 — a moderate spread of 1.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 13 dated records fall in 2022 alone.
NYE METODER (Norway) is the only agency to have returned to pralsetinib, recording 2 separate entries.
pralsetinib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for pralsetinib reads 6 not recommended, 2 no benefit, 1 other and 1 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 16 Jun 2024 | Behandling av lokalavansert eller metastatisk RET-mutert medullær skjoldbruskkjertelkreft (MTC) eller RET-fusjonspositiv… | decision recorded | source |
| HIRA (South Korea) | 6 Jul 2023 | 1. RET 융합 양성 국소 진행성 또는 전이성 비소세포폐암 2. RET 변이 국소 진행성 또는 전이성 갑상선 수질암 | not reimbursed | source |
| DMC (Denmark) | 29 Mar 2023 | Patienter med ikke-småcellet lungekræft med RET-fusion | Delvist anbefalet | source |
| SMC (Scotland) | 13 Mar 2023 | As monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously tr… | withdrawn | source |
| AIFA (Italy) | 17 Nov 2022 | Gavreto è indicato in monoterapia per il trattamento in linee successive alla prima di pazienti adulti con cancro del po… | innovative status not granted · reimbursed class H | source |
8 further decisions for pralsetinib, across 8 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- selpercatinib — divergent outcome (not recommended vs recommended) on a shared indication
- nivolumab — divergent outcome (not recommended vs recommended) on a shared indication
- osimertinib — divergent outcome (not recommended vs recommended) on a shared indication
- durvalumab — divergent outcome (not recommended vs recommended) on a shared indication
- tislelizumab — divergent outcome (not recommended vs recommended) on a shared indication
- afatinib — divergent outcome (not recommended vs recommended) on a shared indication
Coverage: 13 decisions for pralsetinib from 12 agencies, 2021 to 2024. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.